CVT’s Ranexa Approved For Second-Line Angina
This article was originally published in The Pink Sheet Daily
Executive Summary
The partial fatty oxidation inhibitor will launch in late March.
You may also be interested in...
CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson
CV Therapeutics and Astellas Pharma submitted an NDA for their novel cardiac imaging stress agent regadenoson May 14, CVT told "The Pink Sheet" DAILY
CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson
A2A-adenosine agonist could see FDA action by mid-March 2008.
CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson
A2A-adenosine agonist could see FDA action by mid-March 2008.